North America Autotransfusion System Market - 2025-2033

The North American autotransfusion system market reached US$286.52 million in 2024 and is expected to reach US$549.78 million by 2033, growing at a CAGR of 7.6% during the forecast period 2025-2033.

Autotransfusion refers to a medical process in which a patient receives their blood for transfusion instead of banked allogenic (donor) blood. Autotransfusion systems collect, process, and reinfuse a patient's blood during surgical procedures. Blood lost at the surgical site is gathered and can be reinfused into the same patient either during or after the operation, as necessary. This technique enhances patient safety by utilizing their blood and effectively manages blood loss during surgery.

Market Dynamics: Drivers & Restraints

Rising Number of Surgeries with Maximum Blood Loss

The rising number of surgeries associated with significant blood loss is expected to drive the autotransfusion system market as healthcare providers increasingly seek effective solutions for managing intraoperative blood loss. Surgeries such as total hip arthroplasty (THA) and total knee arthroplasty (TKA), coronary artery bypass grafting (CABG), and valve replacements, along with other surgeries with maximum blood loss, are demanding patient blood management systems and equipment.

As the volume of these surgeries rises, coupled with the growing emphasis on patient blood management strategies, the adoption of autotransfusion systems is likely to increase, providing a safer alternative to allogeneic transfusions and enhancing overall patient outcomes.

With the rising number of cardiac surgeries, such as coronary artery bypass grafting (CABG) and valve replacements, the demand for autotransfusion systems is expected to rise due to the high volume of blood loss associated with these procedures. For instance, the National Institute of Health in 2023 stated that almost 400,000 CABG surgeries are performed each year, making it the most commonly performed major surgical procedure.

The rising surgical volumes of orthopedic surgeries, the need for advanced patient blood management devices is rising to reduce blood loss. For instance, the National Institute of Health in 2023 stated that based on 2019 total volume counts, their model forecasts an increase in THA procedures of 176% by 2040 and 659% by 2060. The estimated increase for TKA is projected to be 139% by 2040 and 469% by 2060.

High Costs of Autotransfusion Systems

The high costs associated with autotransfusion systems present a significant restraint in the North America autotransfusion system market, affecting both healthcare providers and patients.

The high costs associated with autotransfusion systems, particularly highlighted by the Haemonetics Corporation Cell Saver Elite PlusBlood Recovery System, which is priced at around USD 5,032.68, pose a significant restraint in the North America autotransfusion system market. This financial barrier impacts healthcare providers' ability to adopt the technologies, especially in smaller facilities or those operating on limited budgets.

The initial investment required for autotransfusion systems can be considerable. The financial strain associated with such investment often leads to reluctance to purchase advanced medical equipment that could enhance patient care and safety during surgical procedures, and thus hampers device adoption.

In addition to the purchase price, ongoing maintenance and operational expenses further complicate the financial landscape. Autotransfusion systems require regular servicing and calibration to ensure they operate effectively and safely.

Segment Analysis

The North America autotransfusion system market is segmented based on product type, technique, application, and end user.

Product Type:

The intraoperative autotransfusion systems from the product type segment are expected to dominate the autotransfusion system market with the highest market share.

Intraoperative autotransfusion systems (IATS) are medical devices designed to recover a patient's blood lost during surgery and reinfuse it back into the patient. This technique, also known as intraoperative blood salvage (IOS), minimizes the need for allogeneic blood transfusions, reducing risks like transfusion reactions and disease transmission. Blood is collected through suction devices and anticoagulants, and then filtered and processed using centrifugation to separate red blood cells from plasma.

The intraoperative autotransfusion systems segment is expected to grow due to various factors like product launches, increasing surgical procedures, a shift towards autologous transfusion, technological advancements, and healthcare infrastructure improvements.

Moreover, intraoperative autotransfusion systems in surgical settings collect and reinfuse a patient's blood lost during surgery, reducing the need for donor blood transfusions and minimizing risks of transfusion-related reactions, infections, and immunosuppression. This method is particularly beneficial in surgeries with high blood loss, such as cardiovascular, orthopedic, and trauma surgeries. It enhances patient safety, supports faster recovery, and contributes to cost-effective surgical care by decreasing reliance on banked blood supplies.

Competitive Landscape

The major North America players in the autotransfusion system market include Fresenius SE & Co. KGaA, LivaNova PLC, Medtronic, Becton, Dickinson and Company, Zimmer Biomet Holdings, Inc., Haemonetics Corporation, Terumo Corporation, Procell Surgical Inc., and Teleflex Incorporated, among others.

Key Developments

• In March 2023, Haemonetics Corporation received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on the next-generation software for the Cell Saver Elite+ Autotransfusion System, with full market release available.

Why Purchase the Report?

• Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The North America autotransfusion system market report delivers a detailed analysis with 42 key tables, more than 43 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.